<DOC>
	<DOCNO>NCT00268307</DOCNO>
	<brief_summary>The goal study determine safety give patient 's bone marrow-derived stem cell deliver catheter ( tube ) coronary artery ( blood vessel heart ) . Stem cell simple cell produce bone marrow develop many type cell . It possible cell decrease size damage cause heart heart attack increase pump efficiency heart ; decrease due heart attack . The stem cell take bone marrow give back heart vessel .</brief_summary>
	<brief_title>Bone Marrow Stem Cell Infusion Following Heart Attack</brief_title>
	<detailed_description>This protocol test hypothesis intracoronary infusion autologous , unfractionated , bone marrow mononuclear cell attenuate infarct size improve left-ventricular function 60 patient follow acute anterior myocardial infarction undergone successful revascularization PTCA/stenting .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients age least 21 year age Patients acute anterior myocardial infarction limit proximal midLAD artery diameter least 2.5 mm . Ability undergo cell therapy procedure within 2 7 day follow acute MI PTCA/stenting . Ejection fraction follow reperfusion PTCA/stenting 30 % 50 % assessed leftventriculography echocardiography . Consent protocol agree comply followup visit study . History sustain ventricular arrhythmia relate acute myocardial infarction ICD . Require coronary artery bypass surgery percutaneous revascularization due presence residual coronary stenosis &gt; 70 % luminal obstruction noninfarct related vessel . History malignancy within past 5 year exclude nonmelanoma skin cancer cervical cancer insitu . History anemia ( Hb &lt; 9.0 mg/dl ) . History thrombocytosis . PT PTT great upper limit normal . Life expectancy less one year . Patients chronic dialysis . History untreated alcohol drug abuse . Currently enrol another Investigational drug device trial . History stroke TIA within past 6 month . History severe valvular heart disease ( aortic valve area &lt; 1.0 cm2 &gt; 3+ mitral regurgitation . Pregnancy Subjects HIV , hepatitis B C positive . Patients active inflammatory autoimmune disease chronic immunosuppressive therapy . Contraindications cardiac MRI</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Cell therapy</keyword>
</DOC>